Grifols reaffirms guidance for 2025
Grifols (GRFS) said: “Grifols remains focused on the continued execution of its strategic plan and reaffirms its guidance for FY2025. Due to the impact of the Inflation Reduction Act on its financial results, Grifols expects to share greater detail in 2025 giving investors and analysts further visibility on its actual performance and underlying momentum. As a result, for 2025, Grifols expects to show both reported figures and LFL figures to make them comparable to previous quarters. LFL figures adjust for the impact on Biopharma performance of both the Inflation Reduction Act Medicare Part D Redesign and the Fee-for-Services reclassification in Q4’24.”
Confident Investing Starts Here:
-
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>
Read More on GRFS:
Terms and Privacy Policy
Recommended Stories
Signal: Foot Locker Stock Rally Might Not Last
Foot Locker stock is approaching a historically bearish trendline
Schaeffer's Investment Research • yesterday
Latest News
- Charged: Tesla’s China-made EV sales down in April
- The London Company Small Cap Strategy Exited its Position in Cannae Holdings (CNNE)
- Nutresa sells Colombian Starbucks franchise stake to Mexico's Alsea
- Analyst Says Palantir Technologies (PLTR) Could See a ‘Longer Pullback’ After ‘Meteoric Rise’
- Why Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy Now
- TotalEnergies looking to sell stakes in Europe biogas units, Bloomberg says